The drug regulator has given nod to conduct phase 1/2 human clinical trial of country’s first indigenous mRNA vaccine candidate. It has been developed by Gennova, Pune, the Department of Biotechnology said recently.

The novel mRNA vaccine candidate, HGCO19, is supported with seed grant under the Ind-CEPI mission of the Department of Biotechnology.

The mRNA vaccines do not use the conventional model to produce immune response. Instead, they carry the molecular instructions to make the protein in the body through a synthetic RNA of the virus.

Also read: RDIF, Hetero to produce over 100 mn doses of Sputnik V vaccine in India

The host body uses this to produce the viral protein that is recognised, thereby, making the body mount an immune response against the disease, a PTI report said.

mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. “The mRNA vaccine is considered safe as it is non-infectious, non-integrating in nature, and degraded by standard cellular mechanisms,” the department of biotechnology was quoted as saying.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.